Printer Friendly

Aminex Therapeutics completes USD4m Series A financing.

M2 EQUITYBITES-November 10, 2015-Aminex Therapeutics completes USD4m Series A financing


Drug development company Aminex Therapeutics Inc announced on Monday that it has closed a USD4m Series A financing round, which includes fifteen new shareholders.

Jim Skaggs, chief executive officer and chairman of Aminex Therapeutics, stated. "The proceeds will be used to finalize Aminex's preclinical testing and prepare for Phase 1/2A human clinical trials to start midyear 2016. Our patented AMX-513 combination therapy enables the immune system to attack cancer by regulating myeloid-derived suppressor cells."

Concurrently, the company has appointed Stacy Hock and Rhonda Rhyne to its board of directors.

Hock is co-owner of Hock LLC and manager of the Joel and Stacy Hock Charitable Fund. She also serves on a number of boards and previously held senior management positions with IBM.

Rhyne is a clinical pharmacist who specialises in taking innovative technologies from the research bench to successful commercialisation. She has worked in the medical technology industry for the past 20 years, serving in executive management for life science companies.

Aminex Therapeutics is focused on discovery, development, and commercialisation of suppressor cell modulators (SCM), a new class of small molecule cancer immunotherapies which enable the immune system to attack cancer by regulating myeloid-derived suppressor cells. The company extensively demonstrated, in animal trials, the potential of its lead drug, AMX-513, to be effective alone and to improve overall therapy when used in combination with other cancer treatments.

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 10, 2015
Previous Article:Fabege declares divestment of 2,619,342 shares in Catena.
Next Article:FedRAMP certification awarded to CSC cloud ARCWRX Platform as a Service (PaaS) offering.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters